Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas.
Paul
Pritha
P
Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Gillory
Lauren A
LA
Kang
JungHee
J
Qiao
Jingbo
J
Chung
Dai H
DH
D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005047:Etoposide / Q000494:pharmacology; D019886:Gastrin-Releasing Peptide / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D009447:Neuroblastoma / Q000473:pathology / Q000628:therapy*; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics*; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000502:physiology; D014750:Vincristine / Q000494:pharmacology
D034741:RNA, Small Interfering; D016159:Tumor Suppressor Protein p53; D014750:Vincristine; D005047:Etoposide; D019886:Gastrin-Releasing Peptide; D011065:Poly(ADP-ribose) Polymerases; D053148:Caspase 3